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Abstract
Background: Antibiotics are among the most widely prescribed medications. The geographic variation in antibiotic
prescribing patterns and associated costs among Medicare Part D recipients have not been described. The purpose
of this study was to assess the regional variation in antibiotic prescriptions and costs among Medicare Part D enrollees
in 2013.
Methods: Retrospective cohort review of all Medicare Part D enrollees in 2013, using the Medicare Provider Utilization
and Payment Data: Part D Prescriber Public Use File. All original or refill prescription claims for antibiotics as listed in the
Part D Prescriber Public Use File were included. Our primary outcomes were total antibiotic claims and antibiotic cost
per Medicare Part D Enrollee. Data were analyzed descriptively by state and by geographic region as defined by the
United States Census Bureau. Antibiotic claims were described overall and by antibiotic class.
Results: Over 54 million outpatient antibiotic claims were filed for Part D enrollees in 2013, representing more than $1.5
billion in total antibiotic expenditures. Antibiotic use was highest in the South (1,623 claims/1,000 enrollees), followed by
the Midwest (1,401 claims/1,000 enrollees), Northeast (1,366 claims/1,000 enrollees), and West (1,292 claims/
1,000 enrollees). Average antibiotic costs per enrollee in each region were as follows: South $46.58, Northeast
$43.70, Midwest $40.54, and West $36.42. Fluoroquinolones were the most commonly prescribed class overall
(12.2 million claims).
Conclusions: Antibiotic use among elderly Medicare enrollees in the United States was highest in the South
region. Fluoroquinolones were the most common antibiotics used in all regions. These patterns could be utilized in
the development of targeted antimicrobial stewardship efforts.
Keywords: Antibiotic stewardship, Fluoroquinolones, Elderly, Macrolides, Claims data, Outpatient prescriptions,
Cephalosporins, Penicillins
Background
The advent of clinically useful antibiotics revolutionized
the practice of medicine; however, the emergence of
antibiotic-resistant organisms has posed a unique challenge
to the utilization of these drugs. Despite advances in drug
development and infection control measures, antibiotic
resistance continues to be a great concern [1]. Each year in
the United States, antibiotic-resistant infections are respon-
sible for an estimated 23,000 deaths and as much as $20
billion in direct healthcare costs [2].
The overuse of antibiotics is a major factor in the
development of resistant organisms [3]. It is estimated
that 30% of outpatient oral antibiotic prescriptions are
inappropriate [4]. Older patients may be dispropor-
tionately impacted by this practice. Outpatient anti-
biotic prescribing rates increased 30% among older
adults from 2000 to 2010 [5]. The use of broad-spectrum
antibiotics in older adults increased 68% during the same
period [5].
Previous studies have examined the geographic vari-
ation of antibiotic prescribing in the United States in
an effort to identify areas where antibiotic stewardship
efforts are most needed. Utilizing data from 2011,
Hicks et al. found that outpatient antibiotic use was
highest in the South and lowest in the West [6]. At
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least two studies found a similar pattern in outpatient
antibiotic prescribing among older adults. It is un-
known if these patterns have continued in more recent
years [4, 7]. Understanding the regional variations in
antibiotic use among older patients is a necessary step
in the development of targeted antimicrobial steward-
ship efforts.
The objective of this study was to describe regional
variation in antibiotic prescribing and costs overall and
by antibiotic class among Medicare Part D enrollees in
2013.
Methods
This study utilized retrospective data from the 2013
Medicare Provider Utilization and Payment Data: Part D
Prescriber Public Use File. The methodology for the
development of this dataset has been described pre-
viously [7]. In brief, the dataset contains information
on the approximately 35.7 million patients enrolled
in the Medicare Part D prescription drug program.
The data were collected using the Centers for Medicare
and Medicaid Services (CMS) 2013 Medicare Part D
Prescription Drug Event (PDE) Standard Analytic File,
which includes PDEs received through June 30, 2014. This
dataset contains information on 99.99% of all final-action
claims submitted by Medicare Advantage Prescription
Drug Plans and stand-alone Prescription Drug Plans. It in-
cludes the total number of prescriptions dispensed (in-
cluding original prescriptions and refills) and total drug
cost. Total drug cost represents the ingredient cost,
dispensing fees, sales tax, and any applicable administra-
tion fees. The total number of enrolled beneficiaries was
determined using a separate publicly available dataset, the
Medicare Advantage/Part D Contract and Enrollment
Data [8]. This dataset contains total enrollment numbers
for both stand-alone Prescription Drug Plans (PDPs) and
Medicare Advantage and Medicare Advantage Prescrip-
tion Drug Plans (MAPDPs) at the state level.
We limited the dataset to all original and refill prescrip-
tion claims for antibiotics. The PDE Standard Analytic File
was searched manually by all authors for generic names
corresponding to systemic antibiotics (excluding topical,
otic, ophthalmic, or inhaled) or antibiotics used for the
treatment of Clostridium difficile (i.e., oral vancomycin
and fidaxomicin). The corresponding brand names for
each identified generic antibiotic were then again searched
manually to remove all non-systemic antibiotics. Any anti-
biotic that could not be definitively identified as systemic
use only (e.g., tobramycin hydrochloride) was excluded
from the final analysis. Additionally, antibiotics that have
significant use for non-infectious indications (e.g., rifaxi-
min) were also excluded. A listing of each included
generic and brand name is included in Additional file 1.
Antibiotics were categorized by therapeutic class, with
parenteral antimicrobials considered separately from oral
formulations. Data were analyzed descriptively by geo-
graphic region, as defined by the United States Census
Bureau. The primary outcomes of interest were claims per
enrollee and cost per enrollee. These outcomes were de-
scribed overall and by antibiotic class. Population antibiotic
claim rates and cost per enrollee were calculated by
dividing the total number of PDEs or total cost, re-
spectively, by the total number of enrollees in both
PDPs and MAPDPs. The cost per claim was calculated
by dividing the total cost for each antibiotic by the
corresponding number of PDEs. We also calculated
coefficients of variance, across both states and regions,
for each of the primary outcomes. All analyses were
performed using STATA v14.1 (StataCorp LP, College
Station, TX). As all data were publicly available and
non-identifiable, this study was deemed exempt by the
institutional review board at The University of Texas
MD Anderson Cancer Center. No external funding
was obtained to complete this study.
Results
Over 54 million outpatient antibiotic claims were filed
for Part D enrollees in 2013, representing 1,452 claims
per 1,000 enrollees and more than $1.5 billion in total
antibiotic expenditures. Across regions, antibiotic claims
per 1,000 enrollees (Fig. 1) were highest in the South
(1,623), followed by the Midwest (1,401), Northeast
(1,366), and West (1,292). Average antibiotic costs per
enrollee in each region (Fig. 1) were as follows: South
($46.58), Northeast ($43.70), Midwest ($40.54), and
West ($36.42). The coefficients of variation across regions
were 10% for claims per 1,000 enrollees and 10% for cost
per enrollee.
Across states, antibiotic claims per 1,000 enrollees
(Fig. 3) were highest in Mississippi (1,911), Tennessee
(1,866), Kentucky (1,837), and Alabama (1,836) and lowest
in Minnesota (1,073), Hawaii (1,098), Oregon (1,120), and
Vermont (1,147). Average antibiotic costs per enrollee
(Fig. 2) were highest in Kentucky ($55.14), West Virginia
($54.43), and the District of Columbia ($53.82) and lowest
in Hawaii ($29.41) and Vermont ($29.70). The coefficients
of variation across states were 15% for claims per 1,000
enrollees and 16% for cost per enrollee; however, state-
level variance in claims and costs tended to cluster non-
randomly by geographic region (Fig. 2 and 3).
Table 1 describes the number of claims by antibiotic
class. Fluoroquinolone antibiotics (12.2 million claims)
were the most commonly prescribed class overall, ac-
counting for 22% of all claims. Oral penicillins (10.0 mil-
lion claims, 19%), macrolides (8.6 million claims, 16%),
and oral cephalosporins (6.8 million claims, 13%) were
also among the most commonly prescribed classes. This
trend was consistent among all regions. Table 2 shows
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the most commonly prescribed antibiotic agents and the
average cost per claim for each drug. Azithromycin was
the most commonly prescribed antibiotic, with 7.2
million total claims and a rate of 194 claims per 1,000
enrollees. Doxycycline, with 3.2 million total claims at a
total cost of $221 million, resulted in the highest cost
per enrollee ($5.93). Fidaxomicin, with 7,857 claims and
a total cost of $23 million, had the highest cost per claim
($2,948). Overall, the ten most frequently prescribed an-
tibiotics accounted for 82% of all antibiotic prescription
claims while the ten highest cost antibiotics represented
65% of all expenditures. A complete listing of claims and
cost per antibiotic is available in Additional file 2.
Discussion
This study described national antibiotic prescribing and
costs among Medicare Part D enrollees in the United
States by geographic region and found that the highest
rate of prescribing occurs in the South census region.
Importantly, this study represents one of the first to use
publicly available data to characterize antibiotic prescrib-
ing trends at a national level, highlighting the potential
for this dataset to serve as a new tool for researchers
and public health authorities to understand broad trends
in prescribing practices.
We found an overall antibiotic prescribing rate of
1,452 claims per 1,000 Part D enrollees, which is
Fig. 1 Antibiotic claims and cost for Medicare Part D Beneficiaries by U.S. census region (data from this study)
Fig. 2 Antibiotic claims per 1,000 Medicare Part D enrollees, by state (data from this study, generated using http://choropleth.us/)
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substantially higher than previous estimates of antibiotic
use in this population. Among adults ≥65 years old,
Hicks et al. reported 1,048 prescriptions per 1,000 persons
in 2011 [6, 9]. In an analysis of National Ambulatory
Medicare Care Survey (NAMCS) and National Hospital
Ambulatory Medicare Care Survey (NHAMCS) data,
Fleming-Dutra et al. estimated that there were just 617
antibiotic prescriptions per 1,000 persons ≥65 years old in
2010–2011 [4]. One reason for this difference is that these
two studies analyzed data from the general population,
while our study focused on Medicare Part D enrollees
only. Furthermore, both studies relied on estimates
derived from samples rather than direct measurements
of claims, number of enrollees, and costs, potentially
accounting for this variance.
Previous studies have characterized outpatient regional
antibiotic prescribing trends in the United States and found
similar prescribing patterns, with antibiotic use highest in
the South region and lowest in the West [6, 7, 10]. Of par-
ticular relevance to our study, a subgroup analysis of
patients ≥65 years old using 2011 data from the IMS Health
Xponent database showed that prescription claims were
highest in the south (1,160 prescriptions per 1,000 persons)
and lowest in the West (882 prescriptions per 1,000).[6]
The underlying causes of these geographic variations can-
not be established from our data; however, at least one prior
study found that regional patterns of antibiotic use were
not significantly correlated with the prevalence of diagnoses
for which antibiotics are commonly indicated (e.g., bacterial
pneumonia) [7]. Differences in the occurrences of acute
nasopharyngitis and nonspecific acute respiratory tract
infections also failed to account for the variation [7]. We
were unable to identify any regional epidemics which might
influence the geographic distribution of antibiotic use.
Fig. 3 Antibiotic cost (in 2013 U.S. Dollars) per Medicare Part D enrollee, by state (data from this study, generated using http://choropleth.us/)
Table 1 Claims per 1,000 enrollees by antibiotic class and
region
Region
Class Midwest Northeast South West Overall
Fluoroquinolone 298 303 379 287 326
Oral Penicillin 265 279 282 241 269
Macrolide 210 229 253 211 229
Oral Cephalosporin 188 158 201 169 183
SMX-TMPa 124 102 146 110 125
Tetracycline 101 85 115 83 99
Nitrofurantoin 63 61 79 58 67
Parenteral 30 33 35 28 32
Other 133 117 134 106 122
aSMX-TMP, sulfamethoxazole-trimethoprim
















a2013 United States Dollars
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Additionally, such an epidemic would be an unlikely ex-
planation for such variation given the similar findings of
other studies conducted in previous years. We were also
unable to correlate the level of antibiotic use to the propor-
tion of Medicare enrollees in each region who qualified by
age versus disability. A previous study found that black race
and lack of health insurance were independent predictors
of lower prescribing rates of broad-spectrum antibiotics for
acute respiratory tract infections [11]. However, the propor-
tion of Medicare enrollees who are black is highest in the
South region, indicating that the high rate of antibiotic use
occurs despite, rather than because of, differences in race
[12]. A 2015 study found that areas with more prescribers
per capita or a higher proportion of female, obese, or black
patients had higher rates of antibiotic prescribing.[6] Con-
versely, areas with higher rates of 4-year college education
and per capita income had lower rates of antibiotic pre-
scribing [6]. At least one study has suggested that excessive
antibiotic use is only one component of a more broad pat-
tern low-quality prescribing in certain locations [13]. Other
research suggests that variations in antibiotic use are likely
due to a wide range of factors which vary between regions,
including comorbidities, patient attitudes towards health-
care, formulary restrictions, physician values, practice
volume, and medical culture in general [11]. Together,
these findings suggest that any intervention aimed at
unnecessary regional variations in antibiotic prescribing
must address multiple societal and economic factors.
Appropriate antibiotic use is of paramount importance
in elderly patients because of their higher risk for
antibiotic-related adverse reactions (e.g., Clostridium
difficile infection) and complications from drug-drug
interactions, such as QT interval prolongation [14]. On
the other hand, elderly patients are also more susceptible
to adverse outcomes from untreated infections due to
the presence of multiple comorbid conditions [15].
Consequently, it is critical to limit unnecessary anti-
biotic prescribing in this population while also ensur-
ing that infections are properly treated with antibiotics
when indicated.
The combination of drug use and cost data may allow
for prioritization of any interventions aimed at reducing
inappropriate antibiotic prescribing. The fluoroquino-
lones (i.e., levofloxacin, moxifloxacin, and ciprofloxacin)
were among the most commonly prescribed agents in
our study, with a prescribing rate of 326 claims per
1,000 enrollees, or 22% of all claims. This class of antibi-
otics is notable for its association with infrequent, yet
severe, adverse effects which may be more likely to
occur in elderly patients [16, 17]. Furthermore, they are
implicated in the development of several types of
antibiotic-resistant bacteria [18, 19]. The FDA recently
advised that the risks of fluoroquinolones outweigh the
benefits for patients with uncomplicated infections as
many other treatment options exist [20]. Interventions
aimed at limiting the use of fluoroquinolones in Medi-
care Part D enrollees may therefore be of particular
benefit. Azithromycin, the most commonly prescribed
single antibiotic at 194 claims per 1,000 enrollees, is
associated with a small but significant increased risk of
cardiac events compared to other antibiotics, with bene-
fit outweighing risk when used appropriately [21, 22]. As
recent studies have demonstrated that over half of all
prescriptions for upper respiratory tract infections are
inappropriate, interventions designed to decrease the
use of azithromycin, which is commonly used for this
purpose, may be similarly beneficial [7, 23]. Finally,
doxycycline was the most costly antibiotic despite being
only the eighth most commonly prescribed; as such, it
may be a reasonable option for cost-containment inter-
ventions as the cost of long-available generic medica-
tions continues to increase [24].
Our findings indicate the need for stewardship inter-
ventions to promote appropriate antibiotic use where
the burden is highest. Prescribing rates in regions with
lower antibiotic use could serve as useful benchmarks
when determining goals for reduction. Several types of
interventions to reduce inappropriate antibiotic prescrib-
ing have been studied in the outpatient setting, including
provider and patient education, provider feedback, com-
munication skills training, restriction policies, and integra-
tion of rapid diagnostics [25]. All types appear effective,
and none have been associated with adverse effects on
patient outcomes or drug spending [25]. However, further
study is needed on the feasibility and effectiveness of these
interventions at the population level.
This study has several potential limitations. First, the
dataset only contains patients enrolled under the Medi-
care Part D prescription drug program (i.e., about two-
thirds of all Medicare beneficiaries), and may not repre-
sent antibiotic prescribing patterns for all Medicare
beneficiaries or elderly patients. Furthermore, we are
unable to determine the appropriateness of antibiotic
prescribing using this dataset, and it is important to
note that lower prescribing rates do not necessarily re-
flect more appropriate prescribing. Next, the data are
limited to medications covered by Medicare Part D or
those covered through supplemental benefits; therefore,
the results might underestimate antibiotic prescribing
in this population. Lastly, this study included a single
year of data, which would not capture annual changes
in prescribing patterns.
Conclusions
In summary, antibiotic use among elderly Medicare
Part D enrollees in the United States was highest in the
South region, confirming the regional variation seen in
prior years and in other populations. Fluoroquinolones
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were the most common antibiotics used in all regions.
These patterns could be utilized in the development of
systematic antimicrobial stewardship efforts.
Additional files
Additional file 1: Generic and brand names of antibiotics included in
the final analysis. (DOCX 15 kb)
Additional file 2: Number and cost of claims for included antibiotics.
(DOCX 19 kb)
Acknowledgements
We gratefully acknowledge Samuel A. Shelburne III, MD, PhD and Frank P.
Tverdek, PharmD for their thoughtful comments and insight on this
manuscript.
Funding
No external funding was obtained in the completion of this work.
Availability of data and materials





mcradvpartdenroldata/.Additional data are available in the Additional files 1 and 2.
Authors’ contributions
Study design: KRR, SLA; Data acquisition: SLA; Data analysis: AA, KRR, SLA;
Manuscript writing: AA, KRR, SLA. All authors read and approved the final
manuscript.
Competing interests
SLA: Advisory boards for Astellas, Allergan, and Theravance. Speaker’s bureau
for Merck. AA, KRR: No competing interests to declare.
Consent for publication
No information related to individual patients is presented in this study.
Ethics approval and consent to participate
This study was reviewed and approved with a waiver of the requirement for
informed consent by the MD Anderson Cancer Center institutional review
board.
Author details
1College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
2Pharmacotherapy Education and Research Center, The University of Texas
Health Science Center at San Antonio, San Antonio, TX, USA. 3Division of
Pharmacy, The University of Texas MD Anderson Cancer Center, 1515
Holcombe Blvd, Unit 0090, Houston, TX 77030, USA. 4Center for Antimicrobial
Resistance and Microbial Genomics, UTHealth McGovern Medical School,
Houston, TX, USA.
Received: 9 August 2016 Accepted: 3 December 2016
References
1. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett
JG, Edwards Jr J. Infectious diseases society of a: the epidemic of antibiotic-
resistant infections: a call to action for the medical community from the
infectious diseases society of America. Clin Infect Dis. 2008;46(2):155–64.
2. Centers for Disease Control and Prevention. Antibiotic resistant threats in
the United States. 2013. Available at: http://www.cdc.gov/drugresistance/
pdf/ar-threats-2013-508.pdf. Accessed 6 Mar 2015.
3. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic
prescribing in primary care on antimicrobial resistance in individual patients:
systematic review and meta-analysis. BMJ. 2010;340:c2096.
4. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File Jr TM,
Finkelstein JA, Gerber JS, Hyun DY, Linder JA, et al. Prevalence of
inappropriate antibiotic prescriptions among US ambulatory care visits,
2010–2011. JAMA. 2016;315(17):1864–73.
5. Lee GC, Reveles KR, Attridge RT, Lawson KA, Mansi IA, Lewis JS II, Frei CR.
Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC
Medicine. 2014;12(96). doi:10.1186/1741-7015-12-96.
6. Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor Jr TH,
Schrag SJ. US outpatient antibiotic prescribing variation according to
geography, patient population, and provider specialty in 2011. Clin
Infect Dis. 2015;60(9):1308–16.
7. Zhang Y, Steinman MA, Kaplan CM. Geographic variation in outpatient
antibiotic prescribing among older adults. Arch Intern Med. 2012;172(19):
1465–71.
8. Centers for Medicare and Medicaid Services. Medicare fee-for service
provider utilization & payment data part D prescriber public use file: a
methodological overview. Available at: https://www.cms.gov/Research-
Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-
Charge-Data/Downloads/Prescriber_Methods.pdf. Accessed 16 May 2016.
9. Medicare Advantage/Part D Contract and Enrollment Data. In.: Centers for
Medicare and Medicaid Services. https://www.cms.gov/Research-Statistics-
Data-and-Systems/Statistics-Trends-and-Reports/MCRAdvPartDEnrolData/
index.html. Accessed 19 May 2016.
10. Centers for Disease Control and Prevention. Outpatient antibiotic
prescriptions — United States, 2013. Available at: http://www.cdc.gov/
getsmart/community/pdfs/annual-reportsummary_2013.pdf. Accessed 16
May 2016.
11. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum
antibiotic prescribing for acute respiratory tract infections in adult primary
care. JAMA. 2003;289(6):719–25.
12. The Henry J. Kaiser Family Foundation State Health Facts. Distribution
of Medicare beneficiaries by race/ethnicity. Available at: http://kff.org/
medicare/state-indicator/medicare-beneficiaries-by-raceethnicity/.
Accessed 16 May 2016.
13. Alsan M, Morden NE, Gottlieb JD, Zhou W, Skinner J. Antibiotic use in cold
and Flu season and prescribing quality: a retrospective cohort study. Med
Care. 2015;53(12):1066–71.
14. Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in
older adults. Clin Infect Dis. 2005;40(7):997–1004.
15. Houston MS, Silverstein MD, Suman VJ. Risk factors for 30-day mortality in
elderly patients with lower respiratory tract infection. Community-based
study Arch Intern Med. 1997;157(19):2190–5.
16. Owens Jr RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones.
Clin Infect Dis. 2005;41 Suppl 2:S144–157.
17. Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the
elderly: an update. Drugs Aging. 2010;27(3):193–209.
18. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and
community fluoroquinolone use and resistance in Staphylococcus aureus
and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41(4):435–40.
19. Lopez-Dupla M, Martinez JA, Vidal F, Almela M, Soriano A, Marco F,
Lopez J, Olona M, Mensa J. Previous ciprofloxacin exposure is associated
with resistance to beta-lactam antibiotics in subsequent Pseudomonas
aeruginosa bacteremic isolates. Am J Infect Control. 2009;37(9):753–8.
20. FDA Drug Safety Communication. FDA advises restricting fluoroquinolone
antibiotic use for certain uncomplicated infections; warns about disabling side
effects that can occur together. In: U.S. Food and drug administration. 2016.
21. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk
of cardiovascular death. N Engl J Med. 2012;366(20):1881–90.
22. Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ,
Johnson CS, Alvarez CA, Frei CR, Good C, et al. Association of azithromycin
with mortality and cardiovascular events among older patients hospitalized
with pneumonia. JAMA. 2014;311(21):2199–208.
23. Schroeck JL, Ruh CA, Sellick Jr JA, Ott MC, Mattappallil A, Mergenhagen KA.
Factors associated with antibiotic misuse in outpatient treatment for upper
respiratory tract infections. Antimicrob Agents Chemother. 2015;59(7):3848–52.
24. Alpern JD, Stauffer WM, Kesselheim AS. High-cost generic drugs–implications
for patients and policymakers. N Engl J Med. 2014;371(20):1859–62.
25. Drekonja DM, Filice GA, Greer N, Olson A, MacDonald R, Rutks I, Wilt TJ.
Antimicrobial stewardship in outpatient settings: a systematic review. Infect
Control Hosp Epidemiol. 2015;36(2):142–52.
Arizpe et al. BMC Infectious Diseases  (2016) 16:744 Page 6 of 6
